Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ATP6V0E2 antisense RNA 1 (ATP6V0E2-AS1) is a long non-coding RNA (lncRNA) gene transcribed from the antisense strand of the ATP6V0E2 locus. This RNA belongs to the lncRNA and natural antisense transcript molecular classes, meaning it does not code for a protein but may regulate expression of its sense counterpart gene (ATP6V0E2) or other local/regional genes. General roles for antisense RNAs include modulation of splicing, transcription, RNA stability, and translation, often in cis, but the specific molecular and biological function of ATP6V0E2-AS1 remains incompletely characterized. According to public gene databases, variants or altered expression of ATP6V0E2-AS1 may be associated with rare metabolic diseases, such as infantile hypophosphatasia. However, there is no direct evidence that ATP6V0E2-AS1 is a therapeutic target, nor are there any known drugs, clinical biomarkers, or notable safety concerns currently linked to this RNA[7][2][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ATP6V0E2 antisense RNA 1 (ATP6V0E2-AS1).